---
company: Milestone Pharmaceuticals Inc.
ticker: MIST
form: 8-K
filed: 2026-05-13
accession: 0001104659-26-059780
source: https://www.sec.gov/Archives/edgar/data/1408443/000110465926059780/
---

# Milestone Pharmaceuticals (MIST) earnings release, May 13, 2026

Milestone Pharmaceuticals Inc. (MIST) · Form 8-K, Item 2.02 · Filed 2026-05-13 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1408443/000110465926059780/)

Milestone Pharmaceuticals Announces First Quarter

2026 Financial Results and Provides Corporate Update

Montreal and Charlotte, N.C., May 13, 2026 – Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced financial results for the first quarter ending March 31, 2026, and provided corporate and regulatory updates.

“

We’re excited to report on our first quarter of sales for CARDAMYST for paroxysmal supraventricular tachycardia, or PSVT.

Healthcare professionals’ initial reaction to the product is positive and w e are very encouraged by the early breadth of unique prescribers writing for their patients,’’ said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. “

G aining

Express Scripts’ national formulary coverage in

March reflects meaningful early payor adoption, highlighting the value

CARDAMYST offers to insurers. We are also observing clinician enthusiasm for expanded development of etripamil in patients with AFib-RVR, as we have now kicked off our Phase 3 pivotal trial and are actively engaging po tentia l clinical trial sites.”

Launch Progress for CARDAMYST

Clinical Updates and Presentations

E tripamil for Patients with Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

First Quarter

2026 Financial Results

For further details on the Company’s financials, refer to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 13, 2026.

Conference

Call and Webcast Details

Call me™:

Participants can use Guest dial-in numbers above and be answered by an operator OR click the

Call me™ link for instant telephone access to the event. The Call me™ link will be made active 15 minutes prior to scheduled start time.

A replay of the audio webcast of the call will be available under the “Investors and Media” section of Milestone's corporate website, www.milestonepharma.com.

About CARDAMYST

CARDAMYST™ (etripamil) nasal spray is approved by the U.S. Food and Drug Administration (FDA) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. It is a novel calcium channel blocker nasal spray designed as a self-administered rapid response therapy for patients, thereby bypassing the need for immediate medical oversight. The product is intended to provide healthcare providers with a new treatment option to enable on-demand care and patient self-management. This portable treatment may provide patients with active management and a greater sense of control over their condition. CARDAMYST is well studied with a robust clinical trial program that includes a completed Phase 3 clinical-stage program for the treatment of PSVT. Currently, etripamil is in Phase 2 development for treatment of PSVT in pediatric patients and Phase 3 development for control of acute atrial fibrillation with rapid ventricular rate (AFib-RVR) in adults. For more information, please visit

CARDAMYST.com.

Indication

CARDAMYST is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.

IMPORTANT SAFETY

INFORMATION FOR CARDAMYST (etripamil)

What is CARDAMYST?

CARDAMYST is a prescription medicine used to help restore normal sinus heart rhythm in adults who have symptoms of sudden episodes of fast heartbeat called paroxysmal supraventricular tachycardia (PSVT).

It is not known if CARDAMYST is safe and effective in children.

Do not use CARDAMYST if you:

Before using CARDAMYST, tell your healthcare provider about all of your medical conditions, including if you:

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of CARDAMYST?

CARDAMYST may cause serious side effects, including:

The most common side effects of CARDAMYST include:

These are not all of the possible side effects for CARDAMYST. Call your doctor for medical advice about side effects. You may report side effects to FDA at

1-800-FDA-1088.

Please see the full Prescribing Information https://milestonepharma.com/etripamilprescribinginformation.pdf for CARDAMYST.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the control of symptomatic episodic attacks associated with AFib-RVR.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “continue,”

“could,” “demonstrate,” “designed,” “develop,” “estimate,” “expect,”

“may,” “pending,” “plan,” “potential,” “progress,” “will”, “intend” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ... (truncated)s press release include statements regarding: regarding the commercialization and adoption of CARDAMYST; expectations in regards to etripamil’s efficacy; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies, including the FDA, EMA and NMPA; the expected timing of initiation, completion, and results and data of Milestone’s ongoing and planned clinical studies, including the Phase 3 study in AFib-RVR; Milestone’s anticipated cash runway; and other statements not related to historical facts. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, whether Milestone’s future interactions with the EMA will have satisfactory outcomes; whether and when, if at all, Milestone’s MMA for etripamil will be approved by the

EMA; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of Milestone’s clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, international tariffs and conflicts, and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and public health emergencies, and risks related the sufficiency of Milestone’s capital resources and its ability to raise additional capital in the current economic climate. These and other risks are set forth in Milestone’s filings with the U.S. Securities and

Exchange Commission (SEC), including in its annual report on Form 10-K for the year ended December 31, 2025 under the caption

“Risk Factors,” as such discussions may be updated from time to time by subsequent filings Milestone may make with the SEC.

Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contact:

Investor Relations

Kevin Gardner, kgardner@lifesciadvisors.com

Media

Relations

Rebecca

Novak, rnovak@milestonepharma.com

Milestone Pharmaceuticals Inc.

Condensed Consolidated Balance Sheets (Unaudited)

(in thousands of US dollars, except share data)

Milestone Pharmaceuticals Inc.

Condensed Consolidated Statements of Loss (Unaudited)

(in thousands of US dollars, except share and per share data)

## Financial statements

### Income Statement (Three months ended March 31, — (in thousands of US dollars, except share and per share data))

| | Three months ended March 31, – 2026 | Three months ended March 31, – 2025 |
|---|---:|---:|
| Revenues | Product revenue, net | 238 | $— |
| Revenues | Total revenues | 238 |  |
| Operating Expenses | Cost of product sales | 14 |  |
| Operating Expenses | Research and development, net of tax credits | 3,251 | 4,978 |
| Operating Expenses | General and administrative | 4,824 | 5,167 |
| Operating Expenses | Commercial | 15,812 | 10,378 |
| Operating Expenses | Total operating expenses | 23,901 | 20,523 |
| Operating Expenses | Loss from operations | -23,663 | -20,523 |
| Operating Expenses | Interest income | 1,732 | 697 |
| Operating Expenses | Interest expense | -4,135 | -935 |
| Operating Expenses | Net loss and comprehensive loss | -26,066 | -20,761 |
| Operating Expenses | Weighted average number of shares and pre-funded warrants outstanding, basic and diluted | 130,286,033 | 66,285,406 |
| Operating Expenses | Net loss per share, basic and diluted | -0.2 | -0.31 |

### Balance Sheet (March 31, 2026 — (in thousands of US dollars, except share data))

| | March 31, 2026 | December 31, 2025 |
|---|---:|---:|
| Current assets | Cash and cash equivalents | 71,317 | 73,046 |
| Current assets | Short-term investments | 112,899 | 32,914 |
| Current assets | Accounts receivable, net | 1,605 |  |
| Current assets | License receivable | 1,546 | 1,546 |
| Current assets | Research and development tax credits receivable | 425 | 316 |
| Current assets | Prepaid expenses | 1,210 | 1,805 |
| Current assets | Inventory, net | 1,826 | 648 |
| Current assets | Other receivables | 1,425 | 1,646 |
| Current assets | Total current assets | 192,253 | 111,921 |
| Current assets | Operating lease right-of-use assets | 981 | 1,129 |
| Current assets | Property and equipment, net | 500 | 511 |
| Current assets | Total assets | 193,734 | 113,561 |
| Current liabilities | Accounts payable | 10,023 | 5,645 |
| Current liabilities | Accrued liabilities | 9,803 | 7,644 |
| Current liabilities | Operating lease liabilities | 659 | 647 |
| Current liabilities | Deferred revenue | 416 |  |
| Current liabilities | Other current liabilities | 43 | 43 |
| Current liabilities | Total current liabilities | 20,944 | 13,979 |
| Current liabilities | Operating lease liabilities, net of current portion | 366 | 539 |
| Current liabilities | Senior secured convertible notes | 58,192 | 57,191 |
| Current liabilities | Royalty financing obligation, long-term | 78,111 |  |
| Current liabilities | Other long-term liabilities | 72 | 83 |
| Current liabilities | Total liabilities | 157,685 | 71,792 |
| Shareholders’ Equity | Common shares, no par value, unlimited shares authorized, 117,794,417 shares issued and outstanding as of March 31, 2026, 106,236,344 shares issued and outstanding as of December 31, 2025 | 373,702 | 352,619 |
| Shareholders’ Equity | Pre-funded warrants - 16,412,925 issued and outstanding as of March 31, 2026 and 16,412,925 as of December 31, 2025 | 55,649 | 55,649 |
| Shareholders’ Equity | Additional paid-in capital | 63,367 | 64,104 |
| Shareholders’ Equity | Accumulated deficit | -456,669 | -430,603 |
| Shareholders’ Equity | Total shareholders’ equity | 36,049 | 41,769 |
| Shareholders’ Equity | Total liabilities and shareholders’ equity | 193,734 | 113,561 |
